These public medtech companies were identified as attractive for potential M&A based on products, growth, and margins. List does not account for valuations.

Amanda Pedersen

May 23, 2022

25 Slides

In a report published May 20, Mike Matson, a medtech analyst at Needham & Co., called out these 25 public medtech companies as attractive for potential M&A. Matson said he identified companies based on products, growth, and margins. The list does not account for valuations, he cautioned, so some of the companies identified may be too expensive to be acquired based on current valuations.

That said, it does appear to be shifting to more of a buyer's market in medtech, as valuations have dropped significantly. You can read more about the current medtech M&A environment here.

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like